Status and risk factors for depression, anxiety, and insomnia symptoms among adolescents in the post-pandemic era.

Publication date: Feb 05, 2025

Owing to their vulnerability to public health crises, adolescents’ mental health status, and related risk factors in the post-pandemic era in China require examination. This study aimed to lay a foundation for subsequent interventions and mental disorder prevention among adolescents. An anonymous online survey was conducted January 8-18, 2023. The survey comprised two parts. The first part collected personal information. The second part included the nine-item Patient Health Questionnaire, seven-item Generalized Anxiety Disorder Scale, and Pittsburgh Sleep Quality Index. Of 50,666 adolescent participants, 46. 8% displayed depressive symptoms, 31. 5% showed anxiety symptoms, and 47. 9% experienced difficulties initiating sleep within 30 min, while 4. 9% manifested depressive, anxiety, and insomnia symptoms simultaneously. Chi-square tests revealed significant variations in the prevalence of these conditions according to age, sex, coronavirus disease-2019 (COVID-19) infection status, family infection status, and increased screen time (P

Open Access PDF

Concepts	Keywords
China	Adolescent
Coronavirus	Adolescents
Depressive	Anxiety
January	Anxiety
	China
	COVID-19
	COVID-19
	Depression
	Depression
	Female
	Humans
	Insomnia
	Male
	Pandemics
	Post-pandemic era
	Prevalence
	Risk Factors
	Surveys and Questionnaires

Semantics

Type	Source	Name
disease	MESH	depression
disease	MESH	anxiety
disease	MESH	insomnia
disease	MESH	health status
disease	MESH	mental disorder
disease	MESH	Anxiety Disorder
disease	MESH	Sleep Quality
pathway	KEGG	Coronavirus disease
disease	MESH	COVID-19
disease	MESH	infection
pathway	REACTOME	Reproduction
drug	DRUGBANK	Coenzyme M
disease	IDO	quality
disease	IDO	history
disease	MESH	long COVID
disease	IDO	intervention
disease	MESH	lifestyle
disease	MESH	confusion
disease	MESH	sleep disorders
disease	MESH	emerging infectious diseases
disease	MESH	major depressive disorder
drug	DRUGBANK	Adenosine
disease	MESH	morbidity
disease	MESH	Comorbidity
disease	IDO	symptom
disease	MESH	loneliness
disease	IDO	role
disease	MESH	psychological distress
drug	DRUGBANK	Indoleacetic acid
disease	MESH	social problem
disease	MESH	psychosis
disease	MESH	bullying
disease	MESH	suicide
disease	MESH	alexithymia
drug	DRUGBANK	Tretamine
disease	MESH	suicidal ideation
disease	MESH	memory loss
disease	MESH	syndrome
disease	MESH	death
pathway	REACTOME	Physiological factors
drug	DRUGBANK	Isoxaflutole
pathway	REACTOME	Immune System
disease	MESH	uncertainty
disease	MESH	reinfection
disease	MESH	psychological stress
disease	MESH	facial expressions
disease	MESH	posttraumatic stress disorder
drug	DRUGBANK	Trestolone
drug	DRUGBANK	Guanosine
disease	MESH	myopia
drug	DRUGBANK	Troleandomycin
drug	DRUGBANK	Sulfasalazine
disease	MESH	sequelae
disease	IDO	process
disease	MESH	burnout
drug	DRUGBANK	(S)-Des-Me-Ampa

Original Article

(Visited 1 times, 1 visits today)